LOADING…
SPECIFICATIONS
01 / Metabolic / LRG-3
GLP-1 receptor agonist. 3 mg lyophilized vial.
DOSE
QUANTITY
BUNDLE & SAVE
SHIPS
FRI · 2-5 BIZ DAYS
PAY WITH
USDC · SOLANA
REFERENCE
COMPOUND DATA AND PEER-REVIEWED CITATIONS FOR LIRAGLUTIDE. FOR RESEARCH USE ONLY.
COMPOUND INFORMATION · TECHNICAL SPECIFICATIONS
MOLECULAR PROFILE
SYNONYMS
STORAGE REQUIREMENTS
LYOPHILIZED (POWDER)
-20°C · up to 2 years
RECONSTITUTED
2-8°C · up to 30 days
SOURCES & REFERENCES · PEER-REVIEWED RESEARCH · 8 CITATIONS FOR LIRAGLUTIDE
THE NEW ENGLAND JOURNAL OF MEDICINE
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
2016 · PMID 27295427
Marso SP, Daniels GH et al.
VIEW SOURCE →
MOLECULAR MEDICINE (CAMBRIDGE, MASS.)
Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis.
2023 · PMID 37770820
Guo T, Yan W et al.
VIEW SOURCE →
JAMA
IMPORTANT RESEARCH NOTICE
NOT FOR HUMAN CONSUMPTION. THIS PRODUCT IS SOLD EXCLUSIVELY FOR RESEARCH AND EDUCATIONAL PURPOSES. IT IS NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE.
ALL CITATIONS ON THIS PAGE ARE SOURCED FROM PUBMED AND PUBCHEM PUBLIC DATABASES. THEY ARE PROVIDED FOR EDUCATIONAL REFERENCE ONLY AND SHOULD NOT BE INTERPRETED AS MEDICAL ADVICE OR PRODUCT CLAIMS.
BY PURCHASING THIS PRODUCT, YOU CONFIRM THAT YOU ARE A QUALIFIED RESEARCHER AND WILL USE IT IN ACCORDANCE WITH ALL APPLICABLE LAWS.
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
2015 · PMID 26284720
Davies MJ, Bergenstal R et al.
VIEW SOURCE →